US OptionsDetailed Quotes
AZN241018C62500
- 15.55
- +0.90+6.14%
15min DelayClose Oct 14 16:00 ET
15.55High15.35Low
15.35Open14.65Pre Close3 Volume155 Open Interest62.50Strike Price4.65KTurnover116.97%IV-0.06%PremiumOct 18, 2024Expiry Date15.60Intrinsic Value100Multiplier3DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9783Delta0.0058Gamma4.97Leverage Ratio-0.0592Theta0.0057Rho4.87Eff Leverage0.0039Vega
AstraZeneca Stock Discussion
🔸 Chinese Stocks Surge on Return from Holidays as Euphoria Extends. Chinese stocks listed onshore jumped as trading resumed following a week-long holiday, with encouraging home sales and consumption data giving fresh impetus to a rally sparked by Beijing’s stimulus blitz. The benchmark CSI 300 Index and SSEC Index climbed almost 11% in early trading before paring its advance. The measure h...
FDA Approves Osimertinib For Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer After Chemoradiation Therapy; Recommended Dose Is 80mg Daily Until Disease Progression Or Unacceptable Toxicity
The move surpassed Wall Street's expectations. Analysts had generally anticipated a 25 basis point cut, while the futures market had priced in a 61% probability of a 50 basis point cut and a 39% probability of a 25 basis point reduction.
Market Response to First Rate Cut
St...
Gapping up
$Oracle (ORCL.US)$ Shares of Oracle surged over 6.2% as the company increased its revenue forecast for fiscal 2026 and provided strong guidance for the fiscal year 2029.
$Restoration Hardware (RH.US)$ Shares of the home furnishings retailer jumped 18.9% following a robust second quarter. RH reported adjusted earnings per share of $1.69 on revenue of $830 million, surpassing analysts' expectations of $1.56 p...
The upcoming interest rate cuts are poised to benefit the biotech stock industry, setting the stage for strong performance in the coming quarters.
Reasons:
Cheaper Funding: Lower interest rates make it easier for biotech companies to access capital for research and development, accelerating their progress and growth potential.
Attractive Valuations: Biotech stocks are currently trading at attractive levels, offering investors an opportunity to capitalize on the sector's long-term pot...
No comment yet